Derivatives of breast cancer antigen her-2 for therapeutical...

C - Chemistry – Metallurgy – 12 – N

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C12N 15/12 (2006.01) A61K 39/00 (2006.01) A61P 35/00 (2006.01) C07K 14/71 (2006.01) C07K 16/28 (2006.01) C12N 5/06 (2006.01) C12N 5/08 (2006.01) A61K 38/00 (2006.01)

Patent

CA 2402721

The present invention provides synthetic compounds, which are derivatives of the breast cancer antigen her-2 (amino acid residues 774 to 782), antibodies that recognize and bind to these compounds, polynucleotides that encode these compounds, and immune effector cells raised in response to presentation of these epitodes. The invention further provides methods for inducing an immune response and administering immunotherapy to a subject by delivering the compositions of the invention.

La présente invention concerne des composés de synthèse, des anticorps qui reconnaissent et se lient auxdits composés, des polynucléotides codant lesdits composés et des cellules effectrices de l'immunité qui se forment en réaction à la présentation de ces épitopes. L'invention concerne également des méthodes visant à induire une réponse immunitaire, ainsi que des méthodes d'immunothérapie consistant à administrer les compositions selon l'invention.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Derivatives of breast cancer antigen her-2 for therapeutical... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Derivatives of breast cancer antigen her-2 for therapeutical..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Derivatives of breast cancer antigen her-2 for therapeutical... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1614726

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.